Vitamin D receptor and estrogen receptor gene polymorphisms in men with type 2 diabetes: Effects on Bone Metabolism

Yavuz, Dilek Gogas; Yüksel, Meral; Sancak, Seda; Yazıcı, Dilek; Üstay, Özlem; Deyneli, Oğuzhan; Akalın, Sema

doi:10.1007/s40200-022-01048-6

Cited by 3 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different studies have evaluated the ability of BTM to predict the rate of bone loss, noting that higher levels of BTM associate with a greater rate of bone loss. Our results are consistent with previous work describing paradoxically, that OC levels are lower than the references range both in T1D and T2D, reflecting reduced bone formation in both types [ 9 ], [ 10 ], [ 11 ], [ 12 ].…”

Section: Discussionsupporting

confidence: 93%

“…The vitamin D receptor gene ( VDR ) has been extensively studied due to the crucial role of vitamin D in bone metabolism [ 10 , 11 ]. Genetic factors are also of great interest in diabetic patients but evidence is currently insufficient, vary among populations and limited studies combine VDR gene polymorphisms and BTM analysis [ 12 , 13 ]. More knowledge is needed about the genetic contribution to bone metabolism in diabetes and factors that may identify patients who are at high risk of bone loss and therefore are more likely to require future management.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Osteocalcin associates with bone mineral density and VDR gene polymorphisms in type 1 and type 2 diabetes

Ramírez Ruiz,

Varo Cenarruzabeitia,

Martínez Villanueva

et al. 2023

Advances in Laboratory Medicine / Avances en Medicina De Laboratorio

View full text Add to dashboard Cite

Objectives Bone metabolism is impaired in diabetes mellitus (DM). Our objective is to evaluate the association of bone turnover markers (BTM) and vitamin D receptor (VDR) gene polymorphisms with bone mineral density (BMD) in DM type 1 (T1D) and DM type 2 (T2D). Methods 165 patients (53 T1D and 112 T2D) were enrolled. BMD was measured by dual-energy X-ray absorptiometry (DEXA). Plasma osteocalcin (OC), beta-CrossLaps (β-CTX) and N‐amino terminal propeptide of type I collagen (P1NP) and VDR gene polymorphisms were evaluated. Results Participants were 53 T1D (41 years [31–48]) and 112 T2D (60 years [51–66]). BMD were not statistically different between the groups. OC (p<0.001) and P1NP levels (p<0.001) were higher in patients with T1D. The areas under the curve for the prediction of bone pathology were 0.732 (p=0.038) for OC in T1D and 0.697 (p=0.007) in T2D. A significant association was found between lower lumbar BMD and the A allele of BsmI (p=0.03), the A allele of ApaI (p=0.04) and the allele C of the Taql (p=0.046). Also, a significant correlation was found with higher OC levels and the G allele of BsmI (p=0.044), C allele of ApaI (p=0.011), T allele of Taql (p=0.006) and with C allele of FokI (p=0.004). Conclusions The high negative predictive value of the cut-off point for OC suggests that could be useful in excluding the risk suffering bone loss, allowing offering a personalized clinical approach to prevent this pathology.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Osteocalcin associates with bone mineral density and VDR gene polymorphisms in type 1 and type 2 diabetes

Ramírez Ruiz,

Varo Cenarruzabeitia,

Martínez Villanueva

et al. 2023

Advances in Laboratory Medicine / Avances en Medicina De Laboratorio

View full text Add to dashboard Cite

show abstract

“…Diferentes estudios han evaluado la capacidad de la MRO para predecir la tasa de pérdida ósea, observando que niveles más elevados de MRO se asocian a una mayor tasa de pérdida ósea. Nuestros resultados concuerdan con trabajos previos que describen, paradójicamente, que los niveles de OC son inferiores al rango de referencia tanto en la T1D como en la T2D, lo que refleja una menor formación ósea en ambos tipos [ 9 ], [ 10 ], [ 11 ], [ 12 ].…”

Section: Discussionunclassified

“…El gen del receptor de la vitamina D (VDR) ha sido objeto de numerosos estudios, debido al papel esencial que desempeña la vitamina D en el metabolismo óseo [ 10 , 11 ]. Los factores genéticos también son de gran interés en los pacientes diabéticos, pero en la actualidad los estudios son insuficientes, varían entre poblaciones y son limitados los que combinan polimorfismos del gen VDR y el análisis de los MRO [ 12 , 13 ]. Se necesitan más conocimientos sobre la contribución genética al metabolismo óseo en la diabetes y sobre los factores que pueden identificar a los pacientes con alto riesgo de pérdida ósea y, por tanto, con mayor probabilidad de requerir tratamientos en el futuro.…”

Section: Introductionunclassified

La osteocalcina se asocia con la densidad mineral ósea y los polimorfismos del gen VDR en la diabetes tipo 1 y 2

Ruiz,

Cenarruzabeitia,

Villanueva

et al. 2023

Advances in Laboratory Medicine / Avances en Medicina De Laboratorio

View full text Add to dashboard Cite

Resumen Objetivos El metabolismo óseo se encuentra alterado en la diabetes mellitus (DM). El objetivo de este estudio es evaluar la relación entre los marcadores de remodelado óseo (MRO), los polimorfismos en el gen receptor de la vitamina D (VDR) y la densidad mineral ósea (DMO) en la DM tipo 1 (T1D) y tipo 2 (T2D). Métodos Se incluyó a 165 pacientes (53 T1D y 112 T2D). La DMO se midió mediante absorciometría de rayos X de energía dual (DEXA). Se realizó un análisis de la osteocalcina (OC) en plasma, beta-CrossLaps (β-CTX), propéptido aminoterminal del procolágeno tipo 1 (P1NP) y los polimorfismos en el gen VDR. Resultados Se incluyó a 53 pacientes con T1D (41 años (31–48)) y 112 con T2D (60 años [51–66]). No se observaron diferencias estadísticamente significativas en relación a la DMO. Los pacientes con T1D presentaron niveles superiores de OC (p<0,001) y P1NP (p<0,001). Las áreas bajo la curva para la predicción de patología ósea para la OC fueron 0,732 (p=0,038) en T1D y 0,697 (p=0,007) en T2D. Se observó una relación estadísticamente significativa entre el alelo A de BsmI (p=0,03), el alelo A de ApaI (p=0,04) y el alelo C de Taql (p=0,046) y una menor DMO. Así mismo, se encontró una correlación significativa entre los niveles elevados de OC y el alelo G de BsmI (p=0,044), el alelo C de ApaI (p=0,011), el alelo T de Taql (p=0,006) y el alelo C de FokI (p=0,004). Conclusiones El elevado valor predictivo negativo del punto de corte de la OC indica que la OC podría ser útil a la hora de descartar el riesgo de pérdida ósea, lo que permitiría diseñar un tratamiento personalizado para prevenir dicha patología.

show abstract

“…Rapid bone loss is caused by certain factors, weight gain and obesity [17,18], delayed menopause, and postmenopausal bone loss are typically linked to affect by 17 beta-hydroxysteroid genes and estrogen receptors [19,20].…”

Section: Introductionmentioning

confidence: 99%

The Relationship of Osteoporosis with Menopause: Review of Article

Alsarraje¹,

Alhyali²

2022

IJRMST

View full text Add to dashboard Cite

Osteoporosis is the most problem of women's bone disease, it has a multitude of causes, including menopause. It affects about one in three women. Before a fracture, osteoporosis does not exhibit any clinical symptoms. Important pathology is brought on by fractures. Postmenopausal osteoporosis can be avoided with early diagnosis of this condition before fractures happen; Menopausal hormone therapy (MHT) significantly reduces the fracture risk in all body bones by halting bone loss and degeneration of bone microstructure. The fast bone loss brought on by declining estrogen peaks in the first two to three years following menopause. Even in women with modest fracture risk, MHT is the only antiosteoporosis medication that has been shown to be effective regardless of baseline risk . There is no rationale for using specific, efficient drugs to treat osteoporosis, making MHT the first option for maintaining bone health in women. It is also advisable to evaluate the advantages and risks of MHT. MHT has become the leading therapeutic choice for preserving bone health in early postmenopausal women.

show abstract

Vitamin D receptor and estrogen receptor gene polymorphisms in men with type 2 diabetes: Effects on Bone Metabolism

Cited by 3 publications

References 31 publications

Osteocalcin associates with bone mineral density and VDR gene polymorphisms in type 1 and type 2 diabetes

Osteocalcin associates with bone mineral density and VDR gene polymorphisms in type 1 and type 2 diabetes

La osteocalcina se asocia con la densidad mineral ósea y los polimorfismos del gen VDR en la diabetes tipo 1 y 2

The Relationship of Osteoporosis with Menopause: Review of Article

Contact Info

Product

Resources

About